An expanded access record providing Velmanase Alfa in Alpha-Mannosidosis, sponsored by Chiesi Farmaceutici S.p.A.. Available. Per ClinicalTrials.gov, last updated 2023-09-25.
Sponsored by Chiesi Farmaceutici S.p.A. · Expanded access
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. alpha-Mannosidosis · Chiesi Farmaceutici S.p.A..
Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., this one is the only one of another kind, and was the 11th registered.
24 studies on the registry are indexed under alpha-Mannosidosis; 6 are open to participants now.
Browse alpha-Mannosidosis studies →1 of the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United States
Ages up to 3
By country, each count listing its studies:
Of the 5 alpha-Mannosidosis studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked.
Median enrollment 10 across the 9 interventional studies, 25 across the 2 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Individual patient expanded access requests may be considered for patients who have no other treatment options.
Expanded access may provide access for treatment prior to approval by the local regulatory agency.
Inclusion Criteria:
-
Exclusion Criteria:
-
Also known as: Lamzede, Lamazym, rhLAMAN, recombinant human alpha-mannosidase
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.